Navigation Links
Genta Incorporated Announces First Quarter 2008 Financial Results and Corporate Highlights
Date:5/8/2008

e drug has demonstrated anticancer activity in several clinical trials. Due to the occurrence of several fatalities related to neutropenia, the drug is currently on clinical hold in the U.S. Based upon guidance from FDA, Genta has developed a strategy that is intended to lift the clinical hold, thereby enabling clinical testing to resume. If further studies document efficacy and safety, tesetaxel offers substantial opportunities to improve convenience, safety, and activity for patients who are currently receiving conventional taxanes.

Financial Information

The Company reported a net loss of $9.7 million, or $0.29 per share, for the first quarter of 2008, compared with a net loss of $5.6 million, or $0.21 per share, for the first quarter of 2007. (All share and per-share data have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.)

Research and development expenses were $6.4 million for the three months ended March 31, 2008, compared with $3.4 million for the three months ended March 31, 2007. This increase was primarily due to the recognition in March 2008 of $2.5 million for license payments on tesetaxel, as well as expenses from the AGENDA clinical trial. Selling, general and administrative expenses were $3.6 million for the three months ended March 31, 2008, compared with $4.1 million for the three months ended March 31, 2007. Share-based compensation expenses recognized under Statement of Financial Accounting Standards No. 123 (revised 2004), Share-Based Payment, ("SFAS 123R") declined $0.3 million.

In the fourth quarter of 2006, the Company recorded an expense of $5.3 million that provides for the issuance of 2.0 million shares of Genta common stock, for a settlement in principle of certain class action litigation. At March 31, 2007, the revised estimated value of the common shares portion of the litigation settlement was $3.7 million, based on a closing price of Genta's common st
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. Genta Incorporated to Present at the BIO CEO & Investor Conference
10. Genta Announces Common Stock Offering of Approximately $3.1 Million
11. Genta Announces Senior Management Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... A new study by researchers from the University ... tiny nanosystems function, unlocking the potential to create ... study, which has been published in the prestigious ... a novel laser technique to examine in rich ... a small cluster containing an acetylene molecule and ...
(Date:7/25/2014)... July 25, 2014 WABC Radio show out ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s ... stem cell therapy in pets. Dr. Harman first visited ... stem cell therapy for pets suffering from osteoarthritis and other ... Veterinary Medicine industry forward. , Young has invited Dr. Harman ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
Breaking Biology Technology:Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6
... Jessica N Ebright 1 and Catherine Bowes Rickman 1, 2, ... Biology, Duke University Medical Center, Durham, , NC 27710 ... , Duke University Medical Center, Box 3802, Durham, NC ... bowes007@duke.edu , , ...
... Julio E Celis 1 , Morten stergaard 1 , Pamela Celis 1 , Hanne ... 2 , 1 Department of Medical Biochemistry ... University of Aarhus, Aarhus, Denmark , 2 Department ... Bladder cancer comprises a broad spectrum of tumors that includes ...
... Diana Davis, Aiguo Zhang, Jim Torrence, and Emily Dale, Bio-Rad Laboratories,Inc., 2000 Alfred Nobel ... Introduction , ... The concentrations of analytes in these assays ... standard curve. A regression analysis is performed to derive , ...
Cached Biology Technology:Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 2Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 3Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 4Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 5Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 6Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 7Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 2Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 3Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 4Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 5Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 6Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 7Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 9Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 10Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 11Selection of Standards for Bio-Plex Cytokine Assays, Rev A 2Selection of Standards for Bio-Plex Cytokine Assays, Rev A 3Selection of Standards for Bio-Plex Cytokine Assays, Rev A 4Selection of Standards for Bio-Plex Cytokine Assays, Rev A 5Selection of Standards for Bio-Plex Cytokine Assays, Rev A 6Selection of Standards for Bio-Plex Cytokine Assays, Rev A 7Selection of Standards for Bio-Plex Cytokine Assays, Rev A 8
(Date:7/25/2014)... Ravi Birla, associate professor of biomedical engineering at ... textbook on tissue engineering and artificial organ development., ... a comprehensive guide to entering into the field ... and professor of biomedical engineering at UH, served ... said that while there are other published books ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... Researchers at Albert Einstein College of Medicine of Yeshiva ... single gene in living cells. In an unprecedented study, published in ... were able to follow, in real time, the process of gene ... molecules of messenger RNA (mRNA) that go on to ...
... A study of DNA rearrangements in roundworm chromosomes may offer ... tumors. A report of the research led by University ... was published in the April 22 online edition of the ... region of repetitive DNA sequence that protects the ends of ...
... Infection Research (HZI) in Braunschweig, Germany have discovered a new, ... cells: In this entry mode, the bacteria exploit the muscle ... cytoplasm. Thus, the strategies Salmonella use to infect ... World Health Organization, the number of Salmonella infections ...
Cached Biology News:Scientists observe single gene activity in living cells 2Study in roundworm chromosomes may offer new clues to tumor genome development 2Salmonella utilize multiple modes of infection 2
... purified chicken intestinal cytoplasmic 1,25-(OH)2D3 receptor ... (VDR) from human, rat, mouse, hamster, ... This antibody does not cross-react with ... detects both the occupied and unoccupied ...
... integration of 2D polyacrylamide gel electrophoresis (2D-PAGE) ... as a core technology platform for proteomic ... for complex samples limited only in the ... and large proteins. Quantitative image based analysis ...
...
... in Refrigerated Vapor Trap Models RVT100, RVT400, ... Models UVS400, UVS400A and UVS800DDA., A non-corrosive, ... use for temperatures ranging from -105 to ... stability and does not evaporate. Far superior ...
Biology Products: